Log in
NASDAQ:CYCN

Cyclerion Therapeutics Stock Forecast, Price & News

$2.60
-0.05 (-1.89 %)
(As of 10/21/2020 12:00 AM ET)
Add
Compare
Today's Range
$2.55
Now: $2.60▼
$2.76
50-Day Range
$2.65
MA: $6.37▼
$8.39
52-Week Range
$1.69
Now: $2.60▼
$14.77
Volume974,590 shs
Average Volume425,577 shs
Market Capitalization$88.19 million
P/E RatioN/A
Dividend YieldN/A
Beta1.76
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. Its product candidates include Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, an orally administered central nervous system (CNS)-penetrant sGC stimulator, which is in Phase I trials for neurodegenerative diseases. The company is also discovering liver-targeted sGC and lung-targeted sGC stimulators. Cyclerion Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.83 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CYCN
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.cyclerion.com
Phone857-327-8778
Employees94

Debt

Debt-to-Equity RatioN/A
Current Ratio3.81
Quick Ratio3.81

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.51 million
Price / Sales19.55
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.56 per share
Price / Book0.73

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-123,010,000.00
Net Margins-2,006.33%
Return on Equity-102.19%
Return on Assets-56.08%

Miscellaneous

Outstanding Shares33,920,000
Market Cap$88.19 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$2.60
-0.05 (-1.89 %)
(As of 10/21/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CYCN News and Ratings via Email

Sign-up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cyclerion Therapeutics (NASDAQ:CYCN) Frequently Asked Questions

How has Cyclerion Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Cyclerion Therapeutics' stock was trading at $2.90 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CYCN stock has decreased by 10.3% and is now trading at $2.60.
View which stocks have been most impacted by COVID-19.

When is Cyclerion Therapeutics' next earnings date?

Cyclerion Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Cyclerion Therapeutics.

How were Cyclerion Therapeutics' earnings last quarter?

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) released its quarterly earnings results on Monday, August, 3rd. The company reported ($0.70) earnings per share for the quarter. The company earned $0.75 million during the quarter. Cyclerion Therapeutics had a negative return on equity of 102.19% and a negative net margin of 2,006.33%.
View Cyclerion Therapeutics' earnings history.

Who are some of Cyclerion Therapeutics' key competitors?

Some companies that are related to Cyclerion Therapeutics include RedHill Biopharma (RDHL), AC Immune (ACIU), Concert Pharmaceuticals (CNCE), Trevena (TRVN), iBio (IBIO), Catalyst Pharmaceuticals (CPRX), Bicycle Therapeutics (BCYC), Spero Therapeutics (SPRO), VYNE Therapeutics (VYNE), Syros Pharmaceuticals (SYRS), Magenta Therapeutics (MGTA), Pandion Therapeutics (PAND), Wave Life Sciences (WVE), TFF Pharmaceuticals (TFFP) and NextCure (NXTC).
View all competitors.

What other stocks do shareholders of Cyclerion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclerion Therapeutics investors own include Fulcrum Therapeutics (FULC), Ovid Therapeutics (OVID), Spectrum Pharmaceuticals (SPPI), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Xeris Pharmaceuticals (XERS), Abeona Therapeutics (ABEO), ACADIA Pharmaceuticals (ACAD), Aimmune Therapeutics (AIMT) and Celldex Therapeutics (CLDX).

Who are Cyclerion Therapeutics' key executives?

Cyclerion Therapeutics' management team includes the following people:
  • Dr. Peter M. Hecht, CEO & Director (Age 56, Pay $72.73k)
  • Dr. Mark G. Currie, Pres & Chief Scientific Officer (Age 65, Pay $317.88k)
  • Dr. Andreas Busch Ph.D., Chief Innovation Officer (Age 57, Pay $373.96k)
  • Mr. William Huyett, Chief Financial Officer (Age 64)
  • Ms. Cheryl Gault, Head of Strategy & Corp. Devel.

What is Cyclerion Therapeutics' stock symbol?

Cyclerion Therapeutics trades on the NASDAQ under the ticker symbol "CYCN."

How do I buy shares of Cyclerion Therapeutics?

Shares of CYCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cyclerion Therapeutics' stock price today?

One share of CYCN stock can currently be purchased for approximately $2.60.

How big of a company is Cyclerion Therapeutics?

Cyclerion Therapeutics has a market capitalization of $88.19 million and generates $4.51 million in revenue each year. Cyclerion Therapeutics employs 94 workers across the globe.

What is Cyclerion Therapeutics' official website?

The official website for Cyclerion Therapeutics is www.cyclerion.com.

How can I contact Cyclerion Therapeutics?

Cyclerion Therapeutics' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The company can be reached via phone at 857-327-8778 or via email at [email protected]

This page was last updated on 10/22/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.